Prevalence of diabetes mellitus in patients with acromegaly.

Growth hormone and reproduction: a review of endocrine and autocrine/paracrine interactions. Int J Endocrinol (2014) 0.79

Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary (2016) 0.78

Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. Pituitary (2016) 0.77

Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor. Diabetes Metab Syndr Obes (2015) 0.75

Acromegaly in a non-diabetic cat. JFMS Open Rep (2016) 0.75

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med (1998) 46.95

Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev (2004) 3.14

Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev (2009) 3.06

Guidelines for acromegaly management: an update. J Clin Endocrinol Metab (2009) 2.96

Acromegaly. Clin Endocrinol (Oxf) (1987) 1.44

A simplified Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population. Horm Metab Res (2007) 1.13

Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med (1979) 1.13

Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) (2000) 1.01

[Prevalence of diabetes in acromegaly and Cushing syndrome]. Acta Med Austriaca (2000) 0.90

Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab (2002) 0.90

Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol (2011) 0.89

Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res (2001) 0.86

Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary (2014) 0.86

Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary (2011) 0.85

Glucose tolerance during long term treatment with a somatostatin analogue. Br Med J (Clin Res Ed) (1986) 0.84

Diabetes mellitus in a cohort of patients with acromegaly. Arq Bras Endocrinol Metabol (2011) 0.81

Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab (2009) 0.80

Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms? Endokrynol Pol (2009) 0.80

Clinical experience with Sandostatin LAR in patients with acromegaly. Neth J Med (2001) 0.78

[Influence of age and body weight on plasma glucose levels during an oral glucose tolerance test in subjects without carbohydrate metabolic disturbances]. Ter Arkh (2009) 0.78

Aberrations in carbohydrate metabolism in patients with diagnosed acromegaly, hospitalized in the Endocrinology and Diabetology Department of Collegium Medicum University of Nicolaus Copernicus in Bydgoszcz in the years 2001-2009. Endokrynol Pol (2010) 0.78

Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly. Eur J Endocrinol (2001) 0.78

[Major risk factors of glucose metabolism abnormalities]. Vopr Pitan (2011) 0.78

[Assessment of renal function according to the NHG protocol 'Diabetes mellitus type 2': risk of overestimating the number of diabetes patients with renal dysfunction]. Ned Tijdschr Geneeskd (2007) 2.96

Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study. Diabet Med (2012) 1.75

Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol (2012) 1.70

[The prevalence of the metabolic syndrome in the Netherlands: increased risk of cardiovascular diseases and diabetes mellitus type 2 in one quarter of persons under 60]. Ned Tijdschr Geneeskd (2007) 1.54

Time course of specific AGEs during optimised glycaemic control in type 2 diabetes. Neth J Med (2006) 1.46

Interference from heterophilic antibodies in seven current TSH assays. Ann Clin Biochem (2008) 1.42

The challenge of multidisciplinary research: improving diabetic pregnancy together. Neth J Med (2013) 1.39

[Two patients with mitochondrial respiratory chain disease]. Ned Tijdschr Geneeskd (2008) 1.38

Cyclic Cushing's syndrome: a clinical challenge. Eur J Endocrinol (2007) 1.30

Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis (2007) 1.28

[Efficient and improved diagnosis of osteoporosis by simultaneous bone density measurement and spinal morphometry]. Ned Tijdschr Geneeskd (2008) 1.12

Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med (2002) 1.11

Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med (2004) 1.08

Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia (2005) 1.04

[Tissue-specific changes in cortisol metabolism and their potential role in the metabolic syndrome]. Ned Tijdschr Geneeskd (2005) 1.04

Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. Int J Sports Med (2003) 1.01

Preoperative pharmacological management of phaeochromocytoma. Neth J Med (2006) 1.00

Resource consumption and costs in Dutch patients with type 2 diabetes mellitus. Results from 29 general practices. Diabet Med (2002) 1.00

The nurse specialist as main care-provider for patients with type 2 diabetes in a primary care setting: effects on patient outcomes. Int J Nurs Stud (2002) 0.95

Combined vertebral fracture assessment and bone mineral density measurement: a new standard in the diagnosis of osteoporosis in academic populations. Osteoporos Int (2010) 0.94

Pleiotropic effects of obesity-susceptibility loci on metabolic traits: a meta-analysis of up to 37,874 individuals. Diabetologia (2013) 0.93

Determinants of HbA1c in nondiabetic Dutch adults: genetic loci and clinical and lifestyle parameters, and their interactions in the Lifelines Cohort Study. J Intern Med (2012) 0.91

Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabet Med (2004) 0.91

Type 2 diabetes mellitus is associated with an imbalance in circulating endothelial and smooth muscle progenitor cell numbers. Diabetologia (2012) 0.90

Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. J Intern Med (2010) 0.87

Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study. Osteoporos Int (2008) 0.85

Cardiometabolic treatment decisions in patients with type 2 diabetes: the role of repeated measurements and medication burden. Qual Saf Health Care (2010) 0.85

CETP inhibition in cardiovascular risk management: a critical appraisal. Eur J Clin Invest (2007) 0.82

Serum interleukin-6 in patients with adrenal tumors. Bull Exp Biol Med (2004) 0.81

Do diabetologists recognise self-management problems in their patients? Diabetes Res Clin Pract (2004) 0.79

[Major risk factors of glucose metabolism abnormalities]. Vopr Pitan (2011) 0.78

Tissue factor pathway inhibitor (TFPI) release after heparin stimulation is increased in Type 1 diabetic patients with albuminuria. Diabet Med (2003) 0.78

[Influence of age and body weight on plasma glucose levels during an oral glucose tolerance test in subjects without carbohydrate metabolic disturbances]. Ter Arkh (2009) 0.78

Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox. Scand J Clin Lab Invest (2005) 0.77

Cyclical Cushing's syndrome due to an atypical thymic carcinoid. Neth J Med (2006) 0.76

The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the -629C-->A cholesteryl ester transfer protein promoter polymorphism: role of lecithin: cholesterol acyltransferase activity. Biochim Biophys Acta (2007) 0.76

Time to move from serum creatinine to eGFR. Diabet Med (2007) 0.75

[Doubts as to the cardiovascular safety of rosiglitazone]. Ned Tijdschr Geneeskd (2007) 0.75

Deriving reference values and utilities for the QoL-AGHDA in adult GHD. Eur J Health Econ (2010) 0.75

[Effect of androgens on the biosynthesis of the nuclear fractions of nucleic acids in the rat liver]. Probl Endokrinol (Mosk) (1969) 0.75

[Lipomobilizing factor of blood in the pathogenesis of hyperlipemia in experimental diabetes mellitus]. Probl Endokrinol (Mosk) (1975) 0.75

[Biochemical indicators of metabolic disorders in bone tissue. I. Bone formation]. Klin Lab Diagn (1999) 0.75

[Influence of incubating the serum of donors and diabetes mellitus patients with insulin on its effect with regard to several lipid metabolism indices]. Probl Endokrinol (Mosk) (1972) 0.75

[Combined action of sexual hormones and aurantin in large and small doses of the nucleic acid biosynthesis in rat liver]. Vopr Med Khim (1969) 0.75

[Lipolysis in fatty tissue of patients with adrenohypercorticism]. Vopr Med Khim (1984) 0.75

[Immunologic indices in Itsenko-Cushing disease]. Probl Endokrinol (Mosk) (1985) 0.75

[Long-term follow-up is indicated after surgery for a phaeochromocytoma]. Ned Tijdschr Geneeskd (2006) 0.75

[Changes in functional state of the thyroid gland and thyrotropic activity of the pituitary gland in Cushing's syndrome after unilateral adrenalectomy combined with radiation therapy]. Ter Arkh (1978) 0.75

An unusual cause of hyperandrogenism. Neth J Med (2012) 0.75

[The effect of ultraviolet irradiation of the blood on various hormonal indicators in women with sclerocystic ovaries]. Sov Med (1990) 0.75

[Hypocortisolism associated with nephrotic syndrome]. Ned Tijdschr Geneeskd (2017) 0.75

[Various new data on the state of carbohydrate metabolism in chronic lead poisoning]. Ter Arkh (1979) 0.75

[Effect of estrogens on the nucleic acid synthesis in the rat liver]. Probl Endokrinol (Mosk) (1969) 0.75

[The effect of gonadectomy and of testosterone propionate administration on biosynthesis of cytoplasmatic RNA fractions in rat liver]. Probl Endokrinol (Mosk) (1969) 0.75

[Changes in lipid-carbohydrate metabolism in staphylococcal destruction of the lungs]. Klin Med (Mosk) (1979) 0.75

[Level of substances reacting with 2-thiobarbituric acid in the plasma of healthy people and patients with various endocrine diseases]. Vopr Med Khim (1987) 0.75

[Morphofunctional changes in the adrenal cortex in Cushing's syndrome]. Sov Med (1982) 0.75

[Study of the metabolism of lipids in the blood serum of patients with Weber-Christian panniculitis]. Vestn Dermatol Venerol (1975) 0.75

[Effect of sex hormones on the synthesis of nuclear and cytoplasmic RNA in the liver of growing rats]. Dokl Akad Nauk SSSR (1970) 0.75

[Indicators of lipid and carbohydrate metabolism and insulin content in glucose tolerance test in patients with Itsenko-Cushing's syndrome]. Sov Med (1975) 0.75

[Clinico-biochemical parallels in diverse forms of primary hyperparathyroidism]. Klin Med (Mosk) (1989) 0.75

[Fat-carbohydrate metabolic indices in experimental pancreatitis]. Patol Fiziol Eksp Ter (1973) 0.75

[Hormone levels of the blood of the adrenal veins and inferior vena cava in patients with adrenal and kidney diseases]. Med Radiol (Mosk) (1985) 0.75

Intestinal pseudo-obstruction as a complication of paragangliomas: case report and literature review. Neth J Med (2013) 0.75

[Use of the "extended" minor dexamethasone test in Itsenko-Cushing disease]. Probl Endokrinol (Mosk) (1989) 0.75

[Analysis of a continuous 24-hour glycemic curve by the symmetrization method]. Probl Endokrinol (Mosk) (2009) 0.75

[Missed hyperinsulinaemia in a patient with an insulinoma]. Ned Tijdschr Geneeskd (2005) 0.75

[Biochemical indicators of metabolic disorders in bone tissue. I. Bone resorption]. Klin Lab Diagn (1999) 0.75

[Glucocorticoid adrenal function and clinical implications of hydrocortisone metabolism tests in patients with bronchial asthma]. Klin Med (Mosk) (2003) 0.75

[Individual patient sensitivity to glucocorticoids and hormone resistance in bronchial asthma]. Ter Arkh (1994) 0.75

[Blood level of atherogenic lipids in workers exposed to lead]. Gig Tr Prof Zabol (1983) 0.75

[Alpha-tocopherol concentration of the blood plasma and erythrocytes in patients with symptomatic obesity due to hypothalamo-hypophyseal-adrenal diseases]. Probl Endokrinol (Mosk) (1986) 0.75

[Correlation of HBA(1c) and postprandial glycemia during a standard breakfast test in patients with type 2 diabetes mellitus receiving glibenclamide]. Ter Arkh (2010) 0.75

[Risk of type 2 diabetes mellitus and acute cardiovascular disorders in patients with early disturbances of carbohydrate metabolism]. Klin Med (Mosk) (2012) 0.75

[Role of somatotropic hormone in the dystrophic syndrome of patients with chronic circulatory failure]. Kardiologiia (1982) 0.75

[Study of lipid peroxidation processes in the blood of patients with vasculitis and spontaneous panniculitis and their correction with antioxidants]. Vestn Dermatol Venerol (1987) 0.75

[Insulin secretion in Itsenko-Cushing disease depending upon the expression of diabetic disorders]. Ter Arkh (1977) 0.75

Plasma content of soluble fas antigen in patients with adrenal tumors and tumor-like pathologies. Bull Exp Biol Med (2002) 0.75

[Assessment of water-electrolyte disorders following lung surgery]. Anesteziol Reanimatol (1979) 0.75

[Itsenko-Cushing disease and lipid peroxidation]. Probl Endokrinol (Mosk) (1989) 0.75

[The extratumor mechanisms of osteolysis in multiple myeloma and the means for their correction]. Ter Arkh (1996) 0.75

[Effects of hemofiltration on lipid peroxidation and lipidograms in multiple organ failure syndrome in patients with peritonitis]. Anesteziol Reanimatol (1995) 0.75

[Glycated hemoglobin level is a tool for monitoring the efficiency of treatment in patients with diabetes mellitus in the Moscow Region]. Klin Lab Diagn (2008) 0.75

The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes. Neth J Med (2012) 0.75

[Metabolic function characteristics and respiratory pathology of premature infants]. Vopr Pitan (1982) 0.75

The current total economic burden of diabetes mellitus in the Netherlands. Neth J Med (2017) 0.75

[Biochemical markers of the bone tissue metabolism and bone densitometry in primary hyperparathyroidism]. Klin Lab Diagn (2004) 0.75

[Status of the pancreas in the group of persons participating in liquidation of the sequelae of the accident at the Chernobyl nuclear power plant]. Sov Med (1991) 0.75

Risk stratification for healthcare planning in women with gestational diabetes mellitus. Neth J Med (2016) 0.75

[Peculiarities of pregnancy management after multiple stenting of coronary arteries]. Klin Med (Mosk) (2012) 0.75

[Current methods and functional tests in the diagnosis of endocrinopathy]. Klin Lab Diagn (1994) 0.75

[Low-flow membrane oxygenation of blood in patients with diffuse purulent peritonitis]. Anesteziol Reanimatol (1997) 0.75